Media stories about BioDelivery Sciences International (NASDAQ:BDSI) have been trending somewhat positive recently, Accern reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. BioDelivery Sciences International earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned news articles about the specialty pharmaceutical company an impact score of 46.5397339375782 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the news articles that may have impacted Accern Sentiment’s rankings:
- BioDelivery Sciences (BDSI) Secures Market Authorization Transfer by Health Canada for BELBUCA and Associated … – StreetInsider.com (streetinsider.com)
- BioDelivery Sciences Announces Granting of Market Authorization Transfer by Health Canada for BELBUCA® and Associated Milestone Payment (finance.yahoo.com)
- BioDelivery Sciences International, Inc. (BDSI) Now Covered by HC Wainwright (americanbankingnews.com)
- BioDelivery Sciences Presents Data on BELBUCA® (buprenorphine) Buccal Film at the PAINWeek 2017 Conference – Markets Insider (markets.businessinsider.com)
- BioDelivery Sciences Presents Data on BELBUCA (buprenorphine) Buccal Film at the PAINWeek 2017 Conference (pressreleasepoint.com)
Several analysts have recently commented on the stock. Janney Montgomery Scott raised their price objective on shares of BioDelivery Sciences International from $3.00 to $4.00 and gave the company a “fair value” rating in a research report on Monday, July 24th. ValuEngine downgraded shares of BioDelivery Sciences International from a “hold” rating to a “sell” rating in a research report on Friday, June 2nd. Zacks Investment Research upgraded shares of BioDelivery Sciences International from a “hold” rating to a “buy” rating and set a $3.00 price objective on the stock in a research report on Wednesday, July 12th. HC Wainwright set a $4.00 price objective on shares of BioDelivery Sciences International and gave the company a “buy” rating in a research report on Monday, July 24th. Finally, Roth Capital set a $5.00 price objective on shares of BioDelivery Sciences International and gave the company a “buy” rating in a research report on Tuesday, May 16th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company. BioDelivery Sciences International currently has an average rating of “Buy” and a consensus price target of $4.21.
Shares of BioDelivery Sciences International (BDSI) opened at 3.00 on Wednesday. The company has a market capitalization of $166.43 million, a P/E ratio of 107.14 and a beta of 1.04. BioDelivery Sciences International has a 12 month low of $1.50 and a 12 month high of $3.60. The stock’s 50 day moving average is $3.18 and its 200 day moving average is $2.43.
BioDelivery Sciences International (NASDAQ:BDSI) last posted its earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.04). BioDelivery Sciences International had a net margin of 3.34% and a return on equity of 14.64%. The firm had revenue of $8.70 million during the quarter, compared to analyst estimates of $8.45 million. During the same quarter in the prior year, the firm earned ($0.31) earnings per share. The business’s revenue for the quarter was up 74.0% on a year-over-year basis. On average, equities analysts predict that BioDelivery Sciences International will post $0.12 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This story was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright law. The legal version of this story can be accessed at https://stocknewstimes.com/2017/09/13/biodelivery-sciences-international-bdsi-getting-somewhat-favorable-news-coverage-accern-reports.html.
About BioDelivery Sciences International
BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.
Receive News & Ratings for BioDelivery Sciences International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.